China’s drug industry pivots to AI-powered candidates to drive next wave of deals
China’s pharmaceutical industry is experiencing a significant shift, moving towards artificial intelligence-powered drug candidates to drive its next wave of deals. This pivot follows a record-breaking first half of 2026, which saw cross-border deals for innovative drugs reach an impressive US$110 billion. The country currently accounts for approximately 30 percent of all new drugs under development globally, securing its position as the second-highest worldwide. This strategic focus on AI is expected to further accelerate innovation and transaction volumes within China’s burgeoning drug sector, signaling a new era for pharmaceutical development in the region.
This development highlights a critical evolution in China’s pharmaceutical landscape, underscoring the increasing integration of AI within the drug discovery and development process. For Asia’s tech ecosystem, this signifies a robust demand for AI solutions tailored to complex scientific applications, potentially fostering new collaborations between biotech firms and AI developers. The substantial investment in AI-powered candidates reflects a strategic move by Chinese pharmaceutical companies to enhance efficiency, reduce costs, and accelerate time-to-market for new drugs, thereby strengthening their competitive edge globally.
From a market dynamics perspective, this pivot is likely to attract further venture capital and private equity investment into AI-driven biotech startups within China. It also sets a precedent for other Asian markets to explore similar AI integration strategies in their respective pharmaceutical sectors. The emphasis on innovative drug development, now augmented by AI, positions China as a leading force in global pharmaceutical innovation, with potential ripple effects on intellectual property generation and international partnerships across the broader Asian tech and healthcare landscape.
